1/16
09:16 am
amgn
Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance]
Low
Report
Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance]
1/16
05:41 am
amgn
Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]
Low
Report
Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]
1/15
04:21 pm
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.
1/15
04:21 pm
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.
1/13
07:41 pm
amgn
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]
Low
Report
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]
1/13
07:38 pm
amgn
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer [CNBC]
Low
Report
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer [CNBC]
1/13
06:48 pm
amgn
Amgen CEO says weight loss drug can address ‘patient persistence issue' [CNBC]
Low
Report
Amgen CEO says weight loss drug can address ‘patient persistence issue' [CNBC]
1/12
08:16 pm
amgn
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event [Yahoo! Finance]
Low
Report
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event [Yahoo! Finance]
1/9
06:10 am
amgn
Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
07:05 pm
amgn
Should Amgen's (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? [Yahoo! Finance]
Low
Report
Should Amgen's (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? [Yahoo! Finance]
1/8
03:28 pm
amgn
BioLab Holdings Announces Significant Team Growth Across Key Departments [Yahoo! Finance]
Low
Report
BioLab Holdings Announces Significant Team Growth Across Key Departments [Yahoo! Finance]
1/8
12:20 pm
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a "hold" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a "hold" rating on the stock.
1/8
06:16 am
amgn
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]
Low
Report
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]
1/7
04:01 pm
amgn
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Medium
Report
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
1/7
05:15 am
amgn
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies [Yahoo! Finance]
Medium
Report
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies [Yahoo! Finance]
1/6
05:04 pm
amgn
Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
Low
Report
Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
1/6
12:31 pm
amgn
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal [Yahoo! Finance]
Low
Report
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal [Yahoo! Finance]
1/6
09:46 am
amgn
Dark Blue Therapeutics acquired by Amgen for up to $840 million [Yahoo! Finance]
Low
Report
Dark Blue Therapeutics acquired by Amgen for up to $840 million [Yahoo! Finance]
1/6
09:30 am
amgn
Dark Blue Therapeutics acquired by Amgen for up to $840 million
Medium
Report
Dark Blue Therapeutics acquired by Amgen for up to $840 million
1/6
09:28 am
amgn
Dark Blue Therapeutics acquired by Amgen for up to $840 million
Medium
Report
Dark Blue Therapeutics acquired by Amgen for up to $840 million
1/6
09:00 am
amgn
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Medium
Report
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
1/6
06:52 am
amgn
Zenas' stock drops 51% despite lead asset's Phase III rare disease win [Yahoo! Finance]
Medium
Report
Zenas' stock drops 51% despite lead asset's Phase III rare disease win [Yahoo! Finance]
1/1
05:12 am
amgn
Strong Results and Pipeline Momentum Power Amgen's (AMGN) 2025 Rally [Yahoo! Finance]
Low
Report
Strong Results and Pipeline Momentum Power Amgen's (AMGN) 2025 Rally [Yahoo! Finance]
12/31
07:03 pm
amgn
Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
Low
Report
Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
12/30
09:16 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $310.00 to $360.00. They now have a "buy" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $310.00 to $360.00. They now have a "buy" rating on the stock.